Bicara Therapeutics Inc. - COMMON STOCK (BCAX)
CUSIP: 055477103
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 65,403,762
- Total 13F shares
- 51,165,684
- Share change
- +2,616,551
- Total reported value
- $475,330,436
- Price per share
- $9.29
- Number of holders
- 105
- Value change
- -$6,689,372
- Number of buys
- 76
- Number of sells
- 34
Quarterly Holders Quick Answers
What is CUSIP 055477103?
CUSIP 055477103 identifies BCAX - Bicara Therapeutics Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 055477103:
Top shareholders of BCAX - Bicara Therapeutics Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
11%
|
6,955,993
|
$90,636,589 | — | 31 Mar 2025 | |
| Kiran Mazumdar-Shaw |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
6,304,931
mixed-class rows
|
$83,184,246 | — | 09 Jun 2025 | |
| Biocon Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,523,897
|
$73,155,178 | — | 16 Sep 2024 | |
| Invus Global Management, LLC |
13D/G
|
Raymond Debbane |
9.6%
|
5,216,969
|
$50,656,769 | $0 | 30 Jun 2025 | |
| FMR LLC |
13F
3/4/5
|
Company · Other* |
5.5%
|
3,611,573
|
$47,058,796 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
5%
|
3,267,083
|
$42,570,091 | — | 31 Mar 2025 | |
| Red Tree Management, LLC |
13F
|
Company |
4.8%
|
3,170,509
|
$41,311,732 | — | 31 Mar 2025 | |
| TPG GP A, LLC |
13F
3/4/5
|
Company · Former 10% Owner |
4.6%
|
3,010,425
|
$39,225,838 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
4.2%
|
2,768,975
|
$36,079,744 | — | 31 Mar 2025 | |
| Omega Fund Management, LLC |
13F
|
Company |
3.4%
|
2,204,650
|
$28,726,590 | — | 31 Mar 2025 | |
| BRAIDWELL LP |
13F
|
Company |
3.3%
|
2,162,803
|
$28,181,323 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
3.1%
|
2,000,000
|
$26,060,000 | — | 31 Mar 2025 | |
| James E. Flynn |
3/4/5
|
Possible Members of 10% Group, 10%+ Owner |
—
class O/S missing
|
1,795,174
|
$23,774,208 | — | 17 Sep 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.7%
|
1,798,021
|
$23,429,000 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.1%
|
1,394,676
|
$18,172,629 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.1%
|
1,343,754
|
$18,011,355 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.1%
|
1,341,932
|
$17,485,375 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.8%
|
1,182,900
|
$15,413,187 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.8%
|
1,152,131
|
$15,012,267 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.7%
|
1,091,118
|
$14,217,267 | — | 31 Mar 2025 | |
| FIL Ltd |
3/4/5
13F
|
Other* · Company |
1.6%
from 13F
|
1,013,853
|
$13,426,861 | — | 16 Sep 2024 | |
| Blackstone Inc. |
13F
|
Company |
1.6%
|
1,028,294
|
$13,398,671 | — | 31 Mar 2025 | |
| Foresite Capital Management VI LLC |
13F
|
Company |
1.5%
|
950,000
|
$12,378,500 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.3%
|
833,333
|
$10,858,329 | — | 31 Mar 2025 | |
| Fairmount Funds Management LLC |
13F
|
Company |
1.2%
|
784,170
|
$10,217,735 | — | 31 Mar 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
0.98%
|
643,382
|
$8,383,262 | — | 31 Mar 2025 | |
| Aisling Capital Management LP |
13F
|
Company |
0.87%
|
568,919
|
$7,413,015 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.75%
|
491,652
|
$6,407,478 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.57%
|
370,131
|
$4,822,807 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.56%
|
365,964
|
$4,768,510 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.53%
|
348,690
|
$4,543,431 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.51%
|
336,070
|
$4,378,992 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.46%
|
298,301
|
$3,886,862 | — | 31 Mar 2025 | |
| Napean Trading & Investment Co (Singapore) PTE Ltd |
13F
|
Company |
0.42%
|
275,942
|
$3,595,524 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.32%
|
212,001
|
$2,762,373 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.24%
|
154,212
|
$2,009,383 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.23%
|
153,004
|
$1,993,642 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.2%
|
130,938
|
$1,706,122 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.19%
|
125,695
|
$1,637,806 | — | 31 Mar 2025 | |
| Atle Fund Management AB |
13F
|
Company |
0.18%
|
119,833
|
$1,561,424 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.17%
|
111,383
|
$1,451,320 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.1%
|
68,561
|
$893,350 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
65,854
|
$858,078 | — | 31 Mar 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.07%
|
47,078
|
$613,426 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.06%
|
41,660
|
$558,244 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.06%
|
42,192
|
$549,761 | — | 31 Mar 2025 | |
| Skandinaviska Enskilda Banken AB (publ) |
13F
|
Company |
0.06%
|
38,035
|
$495,596 | — | 31 Mar 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.05%
|
34,430
|
$448,623 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.05%
|
30,601
|
$398,731 | — | 31 Mar 2025 | |
| Nils Lonberg |
3/4/5
|
Director |
—
mixed-class rows
|
53,737
mixed-class rows
|
$397,183 | — | 09 Jun 2025 |
Institutional Holders of Bicara Therapeutics Inc. - COMMON STOCK (BCAX) as of Q2 2025
As of 30 Jun 2025,
Bicara Therapeutics Inc. - COMMON STOCK (BCAX) was held by
105 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,165,684 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Siren, L.L.C., Vestal Point Capital, LP, RED TREE MANAGEMENT, LLC, TPG GP A, LLC, FMR LLC, Deep Track Capital, LP, Omega Fund Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, and BlackRock, Inc..
This page lists
105
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
92
Q2 2025 holders
105
Holder diff
13
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.